Long-term survival of a kidney transplant patient with advanced renal cancer after combination therapy: a case report and literature review.

IF 1.4 4区 医学 Q4 MEDICINE, RESEARCH & EXPERIMENTAL
Chao Peng, Weihao Wang, Jiajun Chen, Shouhua Pan, Gang Xu, Mengyao Li, Lulu Zhang, Yulei Li, Keyuan Zhao, Jing Jin
{"title":"Long-term survival of a kidney transplant patient with advanced renal cancer after combination therapy: a case report and literature review.","authors":"Chao Peng, Weihao Wang, Jiajun Chen, Shouhua Pan, Gang Xu, Mengyao Li, Lulu Zhang, Yulei Li, Keyuan Zhao, Jing Jin","doi":"10.1177/03000605241304640","DOIUrl":null,"url":null,"abstract":"<p><p><i>De novo</i> renal transplant carcinoma, especially in the context of bilateral renal carcinoma, is rare and often presents as small, low-grade papillary renal cell carcinoma (RCC). There is currently no consensus or effective treatment for advanced metastatic RCC after kidney transplantation. A 40-year-old man developed <i>de novo</i> renal transplant carcinoma with venous thrombus and lung metastases 13 years after transplantation. The patient underwent cytoreductive nephrectomy followed by sequential treatment with tyrosine kinase inhibitors (TKI) and anti-PD-1 monoclonal antibodies. After 2 years, the patient showed excellent graft function with no evidence of cancer progression. Despite subsequent graft failure, the disease remained controlled for more than 2 years and the patient survived for more than 3 years, which was significantly longer than the typical survival of 10 to 20 months in patients with advanced kidney cancer. The results suggest that combining cytoreductive nephrectomy with TKI and anti-PD-1 therapy may significantly prolong survival in patients with renal allograft carcinoma.</p>","PeriodicalId":16129,"journal":{"name":"Journal of International Medical Research","volume":"52 12","pages":"3000605241304640"},"PeriodicalIF":1.4000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11694285/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of International Medical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03000605241304640","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

De novo renal transplant carcinoma, especially in the context of bilateral renal carcinoma, is rare and often presents as small, low-grade papillary renal cell carcinoma (RCC). There is currently no consensus or effective treatment for advanced metastatic RCC after kidney transplantation. A 40-year-old man developed de novo renal transplant carcinoma with venous thrombus and lung metastases 13 years after transplantation. The patient underwent cytoreductive nephrectomy followed by sequential treatment with tyrosine kinase inhibitors (TKI) and anti-PD-1 monoclonal antibodies. After 2 years, the patient showed excellent graft function with no evidence of cancer progression. Despite subsequent graft failure, the disease remained controlled for more than 2 years and the patient survived for more than 3 years, which was significantly longer than the typical survival of 10 to 20 months in patients with advanced kidney cancer. The results suggest that combining cytoreductive nephrectomy with TKI and anti-PD-1 therapy may significantly prolong survival in patients with renal allograft carcinoma.

肾移植合并晚期肾癌患者联合治疗后的长期生存:1例报告及文献复习。
肾移植癌,尤其是双侧肾癌,是罕见的,通常表现为小的,低级别的乳头状肾细胞癌(RCC)。对于肾移植后晚期转移性肾细胞癌,目前尚无共识或有效的治疗方法。一例40岁男性肾移植术后13年新发肾移植癌伴静脉血栓及肺转移。患者接受了细胞减减性肾切除术,随后接受了酪氨酸激酶抑制剂(TKI)和抗pd -1单克隆抗体的序贯治疗。2年后,患者表现出良好的移植物功能,没有癌症进展的迹象。尽管随后移植失败,但病情得到了2年多的控制,患者存活了3年多,明显长于晚期肾癌患者10 - 20个月的典型生存期。结果提示,联合TKI和抗pd -1治疗可显著延长同种异体肾移植癌患者的生存期。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.20
自引率
0.00%
发文量
555
审稿时长
1 months
期刊介绍: _Journal of International Medical Research_ is a leading international journal for rapid publication of original medical, pre-clinical and clinical research, reviews, preliminary and pilot studies on a page charge basis. As a service to authors, every article accepted by peer review will be given a full technical edit to make papers as accessible and readable to the international medical community as rapidly as possible. Once the technical edit queries have been answered to the satisfaction of the journal, the paper will be published and made available freely to everyone under a creative commons licence. Symposium proceedings, summaries of presentations or collections of medical, pre-clinical or clinical data on a specific topic are welcome for publication as supplements. Print ISSN: 0300-0605
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信